Voyager Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Voyager Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue80.00250.0140.9137.42171.13104.397.62
Cost of Revenue124.5992.1755.7673.79108.750.000.00
Gross Profit-44.59250.01-14.8637.42171.13104.390.00
Operating Expenses
Research & Development127.3792.1760.7673.79108.75119.7464.91
Selling, General & Administrative35.9235.8230.9837.2534.9936.3433.81
Operating Expenses35.92127.9930.98111.03143.74156.0798.71
Operating Income-80.51122.01-45.84-73.6227.38-51.68-91.10
Other Income/Expense
Interest Income18.3311.721.790.001.660.003.31
Interest Expense0.000.000.00-0.390.000.000.00
Other Income/Expense0.620.002.65-2.81-7.70-1.63-0.68
Income
Income Before Tax-64.34133.74-46.39-71.2036.74-43.60-88.47
Income Tax Expense0.671.410.020.000.000.00-0.18
Net Income-65.00132.33-46.41-71.2036.74-43.60-88.29
Net Income - Continuous Operations-65.00132.33-46.41-71.200.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-75.78138.14-39.65-68.4531.20-44.38-88.98
EBIT-80.51133.74-45.84-73.6227.38-43.60-91.10
Depreciation & Amortization4.734.446.195.173.822.770.00
Earnings Per Share
Basic EPS-1.003.00-1.00-2.001.00-1.00-3.00
Diluted EPS-1.003.00-1.00-2.001.00-1.00-3.00
Basic Shares Outstanding57.6743.0238.3637.6737.1335.9032.07
Diluted Shares Outstanding57.6744.5738.3637.6737.350.0032.07